ecDNA elements have been recognized for over half a century, first described in the mid-1960s through cytogenetic analyses that revealed chromosomal fragments forming circular DNA structures independent of the main chromosomal genome. The clinical significance of ecDNA came into sharper focus in the late 1970s when mouse models demonstrated their role in mediating resistance to chemotherapeutic agents. Since then, mounting evidence highlights that ecDNA are disproportionately abundant in aggressive cancers, where they frequently amplify oncogenes—genes that can transform a normal cell into a tumor cell when overexpressed or mutated. The spatial dislocation from chromosomes endows ecDNA with unique regulatory freedoms, enabling dynamic gene expression that fuels cancer cell adaptability and malignancy.

Dr. Lukas Chavez, a leading scientist specializing in the cancer genome and epigenetics at Sanford Burnham Prebys, underscores the clinical gravity of ecDNA presence in tumors. “The presence of these extrachromosomal DNA loops correlates strongly with worsened patient outcomes, underscoring their potential as both biomarkers and therapeutic targets,” Chavez explains. However, a pressing gap persisted in the field regarding the fidelity of PDX models to faithfully replicate the ecDNA landscape observed in original human tumors. Addressing this gap is critical because the utility of PDX models hinges on their ability to mirror human tumor biology as closely as possible.

To investigate this, the research team undertook a comprehensive analysis of nearly 300 pediatric tumor samples representing over 30 cancer types alongside their corresponding PDX models. Using high-resolution genomic sequencing techniques, they meticulously cataloged ecDNA elements, focusing on copy number variations of oncogenes carried extrachromosomally. The findings were striking—ecDNA were detected in approximately one-third of the tumor samples, reflecting a significant burden in pediatric oncology. Importantly, the oncogene amplification profiles on ecDNA matched those documented in large-scale cancer genomics datasets, reaffirming the clinical relevance of their observations.

A particularly compelling aspect of the study involved comparative genome sequencing of paired human tumors and their PDX counterparts. In over 80% of pairs, ecDNA presence was directly concordant, and the ecDNA sequences themselves were substantially preserved. This genomic fidelity implies that PDX models not only retain the structural features of ecDNA but also maintain the oncogenic potential encoded therein. These data provide robust evidence that PDX models are valid surrogates for studying ecDNA-driven biology in pediatric brain and other cancers.

Beyond bulk genomic analyses, the team harnessed single-cell sequencing technologies to dissect ecDNA distribution at the cellular level within tumors and PDX models. In one tumor-PDX pair, an overwhelming majority of cells contained ecDNA, suggesting a dominant clone driving tumorigenesis. Remarkably, another pair exhibited ecDNA only in a small fraction of tumor cells, yet the derived PDX model showed ecDNA presence in nearly all cells. This finding implies that ecDNA-positive cells possess a selective growth advantage during PDX development, potentially mirroring clonal expansion patterns in vivo.

These observations offer critical insights into tumor heterogeneity and clonal evolution, highlighting ecDNA as a molecular driver that shapes tumor architecture and treatment resistance. Given that ecDNA can dynamically modulate oncogene dosage and gene expression, their selective proliferation in PDX models reinforces the validity of these systems for therapeutic testing. Moreover, the research supports the notion that targeting ecDNA mechanisms, such as their replication or segregation during cell division, could open new avenues for combating aggressive, treatment-resistant cancers.

Looking ahead, the research consortium plans to employ PDX models to longitudinally track ecDNA evolution in response to conventional therapies, including chemotherapy and radiation. By elucidating how ecDNA facilitates cellular adaptation and survival under therapeutic pressure, scientists aim to identify vulnerabilities that can be exploited for more effective interventions. Such efforts could pave the way for precision medicine strategies tailored to the unique ecDNA landscape of individual tumors.

“Our primary goal is to deepen our understanding of ecDNA-mediated treatment resistance and uncover novel therapeutic targets that can improve outcomes for children battling these devastating cancers,” says Dr. Chavez. The study’s insights into the molecular fidelity of PDX models mark a crucial step toward this goal, providing researchers with robust tools to interrogate the complexities of cancer genome plasticity.

This research was made possible through the collaborative efforts of scientists from Sanford Burnham Prebys, Nagoya City University, the University of California San Diego, Rady Children’s Hospital, and Columbia University Irving Medical Center. Supported by prominent funding bodies, including the National Institutes of Health, National Cancer Institute, National Science Foundation, and several foundations dedicated to cancer research, the study epitomizes the power of interdisciplinary collaboration in advancing pediatric oncology.

In sum, this landmark study not only validates the use of PDX models for studying extrachromosomal DNA in childhood cancers but also heralds a new era of targeted therapeutic exploration. As the field evolves, leveraging such models to decode the role of ecDNA in treatment resistance and tumor evolution promises to transform pediatric cancer management, offering hope for more durable remissions and cures.

Subject of Research: Animals

Article Title: Preservation and clonal behavior of extrachromosomal DNA in patient-derived xenograft models of childhood cancers

News Publication Date: 28-May-2026

Web References:

• https://doi.org/10.1186/s13073-026-01676-0
• https://link.springer.com/article/10.1186/s13073-026-01676-0

Image Credits: Sanford Burnham Prebys

Keywords: Cancer, Brain cancer, Oncogenes, Cancer research, Cancer genomics, Genomics, Cancer genome sequencing, Cancer proliferation genes, Tumor suppressors, Single cell sequencing

At its core, ecDNA comprises circular DNA fragments that exist outside the canonical chromosomal structures within cancer cells. Unlike linear chromosomes securely housed in the nucleus, ecDNA is free-floating and capable of rapid amplification. This configuration confers a significant evolutionary advantage to cancer cells, enabling swift genetic alterations that fuel oncogene overexpression. In urothelial carcinoma, ecDNA goes beyond simply copying oncogenes—it orchestrates complex changes to the three-dimensional organization of chromatin, essentially reprogramming the nuclear landscape to favor malignant progression.

The ramifications of this chromatin remodeling are profound. By reshaping three-dimensional interactions within the cell nucleus, ecDNA facilitates aberrant transcriptional programs that drive tumorigenic properties. Such spatial reorganization means oncogenes and other regulatory elements can engage in new, often potent, interactions, promoting transcriptional activation that accelerates tumour growth. This architectural plasticity is a linchpin in how ecDNA mediates both cellular and molecular heterogeneity within urothelial carcinoma lesions.

Moreover, ecDNA’s influence extends into the realm of the tumour microenvironment, modulating the intricate interplay between cancer cells and the immune system. The tumor-immune interface is a battlefield where evasion tactics can determine patient outcomes. ecDNA reshapes this interface by altering gene expression patterns related to immune modulation, potentially dampening immune surveillance mechanisms and enabling tumour cells to evade immune destruction. This immune reprogramming mirrors the aggressive clinical course observed in many urothelial carcinoma cases harbouring ecDNA amplifications.

One particularly striking aspect of ecDNA’s role in urothelial carcinoma is its contribution to genomic instability through accelerating APOBEC3-associated mutational processes. The APOBEC3 family of cytidine deaminases are enzymes that edit DNA, and while they normally function in antiviral responses, their dysregulation introduces a distinctive mutational signature within cancer genomes. The presence of ecDNA exacerbates these mutagenic events, driving an accelerated pace of genetic diversification that fuels tumour evolution and subclonal heterogeneity.

This intratumoural heterogeneity represents one of the foremost challenges in cancer treatment. Tumours composed of genetically diverse cancer cell populations are more likely to develop resistance to therapies, including chemotherapy, targeted agents, and immunotherapies. The role of ecDNA in promoting such plasticity offers an explanation for the frequent clinical observation of therapeutic failure and disease relapse in urothelial carcinoma patients.

Technological advancements have been instrumental in unravelling the mysteries of ecDNA. Cutting-edge sequencing modalities, coupled with sophisticated imaging techniques, have illuminated the prevalence, structure, and functional impact of ecDNA in malignant tissues. Techniques such as long-read sequencing and chromatin conformation capture have enabled researchers to map the rearrangements and three-dimensional networks ecDNA participates in, painting a comprehensive picture of its oncogenic capacity.

Importantly, the potential of ecDNA extends beyond basic research; it heralds new possibilities in clinical diagnostics and patient management. Unlike traditional biomarkers that require invasive tissue biopsies, ecDNA can be detected conveniently via liquid biopsies, including both plasma and urine samples. Given the anatomy of urothelial carcinoma, urine-based assays are particularly appealing, offering a non-invasive window into tumor genomic alterations, which could greatly enhance early detection and real-time monitoring.

Digital pathology further expands the diagnostic repertoire by enabling ecDNA inference from standard histopathological slides. Utilizing advanced algorithms and machine learning, pathologists can identify cellular features suggestive of ecDNA presence without additional invasive procedures. This convergence of molecular biology and computational pathology embodies the precision medicine ethos, streamlining patient stratification and treatment decisions.

The clinical implications are substantial. Incorporation of ecDNA-based biomarkers into standard workflows could revolutionize the management of urothelial carcinoma. Early detection workflows may capture tumours at stages more amenable to curative intervention. Monitoring treatment response and disease progression could become more dynamic and responsive, as ecDNA levels reflect genomic evolution and therapeutic resistance in real-time.

Furthermore, understanding the mechanisms underpinning ecDNA formation and maintenance opens new therapeutic frontiers. Targeting the biogenesis or replication dynamics of ecDNA might blunt oncogene amplification and tumour heterogeneity, sensitizing cancer cells to existing modalities. Emerging inhibitors that disrupt DNA repair pathways or chromatin remodeling proteins integral to ecDNA stability hold promise as adjunct therapies.

Conceptually, ecDNA challenges the dogma of linear chromosomal inheritance as the sole driver of cancer evolution. Its presence underscores the adaptability of tumour genomes, operating through unconventional genetic architectures that accelerate malignancy. This paradigm shift compels researchers and clinicians alike to rethink strategies for combating cancers that exploit ecDNA-driven plasticity.

Future investigations are poised to deepen our mechanistic understanding of how ecDNA interfaces with broader genomic and epigenomic landscapes in urothelial carcinoma. Elucidating the triggers for ecDNA genesis, the cellular machinery involved in its replication and segregation, and its interaction with signalling networks remain critical research frontiers. Translationally, large-scale clinical trials integrating ecDNA biomarker assessments will be key to validating their prognostic and therapeutic utility.

In summation, the discovery of ecDNA’s multifaceted role in urothelial carcinoma marks a watershed moment in oncology. By fundamentally altering chromatin architecture, gene expression, immune interactions, and mutational dynamics, ecDNA fuels the hallmark genomic chaos that defines aggressive cancers. As tools to detect and target ecDNA mature, they hold the promise to transform clinical outcomes for patients facing the formidable challenge of urothelial carcinoma.

Subject of Research: Extrachromosomal DNA (ecDNA) and its roles in urothelial carcinoma progression and clinical applications.

Article Title: Extrachromosomal DNA in urothelial carcinoma: mechanisms and clinical applications.

Article References:
Li, C., Hu, Z., Zhang, W. et al. Extrachromosomal DNA in urothelial carcinoma: mechanisms and clinical applications. Nat Rev Urol (2026). https://doi.org/10.1038/s41585-026-01134-x

Image Credits: AI Generated

Recent research has illuminated the critical role of ecDNA in tumor progression. Studies have documented its contribution to genetic heterogeneity within tumors, making the cancer cells more adaptable and difficult to eradicate. Moreover, the dynamics of ecDNA have profound implications for patient prognosis, as an active presence of ecDNA often correlates with poor outcomes. Despite these insights, the mechanisms by which ecDNA is replicated and maintained have remained elusive. The complexity underlying these biological processes has presented significant challenges for researchers seeking to delineate the functional roles of ecDNA in cancers.

In an important breakthrough, a team of researchers led by Prof. GAN Haiyun from the Shenzhen Institutes of Advanced Technology has made strides in unraveling the intricate relationship between ecDNA maintenance and the DNA damage response (DDR). Their findings, published in the prestigious journal Cell, enrich our understanding of the molecular interplay governing ecDNA biology. The research delineates a reciprocal regulatory relationship between ecDNA dynamics and DDR—an essential pathway that cells activate upon encountering DNA damage.

A significant impediment in ecDNA research has been the lack of reliable and well-controlled cellular models. To address this gap, Prof. GAN’s team employed CRISPR technology to generate two ecDNA-positive cell models. By creating matched pairs of cell lines, they have established a powerful platform for rigorous comparative studies. These engineered models allowed the researchers to generate compelling evidence supporting the notion that ecDNA is not merely a passive participant but actively undergoes replication and stabilization in tumor cells.

Through meticulous experimentation, the team demonstrated that ecDNA replication is not only a distinct process but is also tightly coupled with the activation of the ATM-mediated DDR pathway. In ecDNA-positive cells, enhanced activity of both replication and transcription was observed, highlighting the intricate dynamics of these processes. The researchers pinpointed that the collision of replication machinery or transcription complexes with topoisomerase-DNA complexes could result in the formation of abortive topoisomerase complexes, leading to double-strand breaks. This multifaceted interplay underscores the role of ecDNA in tumor biology and brings to light the risks that heightened replication activity poses to genomic integrity.

Furthermore, the team shed light on the mechanisms responsible for maintaining ecDNA. They uncovered that the alternative non-homologous end joining (alt-NHEJ) pathway is critical for repairing DNA damage associated with ecDNA. The experiments demonstrated that inhibiting essential components of the alt-NHEJ machinery, such as LIG3, resulted in significant disruptions to ecDNA circularization and led to reduced levels of ecDNA in tumor cells. These findings indicate that the maintenance of ecDNA is not merely a passive occurrence but is an actively regulated process that relies heavily on specific DNA repair pathways.

The research also delves into the translational aspects of these discoveries. The findings suggest that targeting the DDR and alt-NHEJ pathways may establish novel treatment strategies for cancers driven by ecDNA. Specifically, the study revealed that inhibiting DDR components selectively compromised the viability of ecDNA-positive cells, which underscores the potential for exploiting these pathways in therapeutic contexts. The implications are profound, as targeting these interactions could provide a dual benefit, undermining tumor survival while preserving normal cellular function.

Prof. GAN emphasized the significance of their findings, stating that their work enhances the understanding of how DDR plays a pivotal role in the dynamics of ecDNA and its evolutionary trajectory in tumors. While these insights are promising, the researchers acknowledge that further investigations are necessary to fully elucidate ecDNA’s impact on tumor heterogeneity, progression, and the mechanisms underlying drug resistance. The potential for therapeutic intervention lies in harnessing these mechanisms, presenting an exciting frontier for oncological research.

The research led by Prof. GAN marks a significant advancement in the understanding of ecDNA and its interplay with DNA damage responses. The insights gained from this study not only advance the field of cancer biology but also pave the way for innovative therapeutic strategies that could improve patient outcomes. Looking ahead, continued exploration of ecDNA dynamics and the associated molecular mechanisms will be crucial for developing effective interventions against tumors characterized by ecDNA-driven adaptations.

As we move forward, the potential for new diagnostics and therapeutic strategies derived from the understanding of ecDNA’s role in cancer progression appears promising. The intricate relationships defined by the research team provide fertile ground for future investigations. Indeed, targeting the pathways responsible for the maintenance and repair of ecDNA could yield transformative approaches in the battle against cancer, offering hope for more effective treatments tailored to individual patients’ tumor biology.

In conclusion, this groundbreaking research illuminates the complexities surrounding ecDNA, particularly its replication and the associated DNA damage response mechanisms that are crucial for tumor growth. By uncovering the relationship between these processes, the study lays the groundwork for future explorations aimed at addressing one of the most pressing challenges in oncology: overcoming the adaptability and resilience of cancer cells driven by extrachromosomal DNA.

Subject of Research: The Role of Extrachromosomal DNA in Tumor Biology and Its Interaction with DNA Damage Response Mechanisms
Article Title: Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors
News Publication Date: 28-Apr-2025
Web References: Cell Journal Article
References: Not Applicable
Image Credits: Not Applicable

Keywords